Study Overview

We are conducting a research study for peanut allergic children. This study evaluates the safety, tolerability, and effectiveness of Dupilumab injections in conjunction with daily peanut oral immunotherapy.

Study Eligibility

Must be between 6 and 17 years of age, and have a physician documented peanut allergy.


For more information, contact the Allergy Research Group 501-364-3031.